JP2011522796A - 抗ウイルス細胞透過性ペプチド - Google Patents

抗ウイルス細胞透過性ペプチド Download PDF

Info

Publication number
JP2011522796A
JP2011522796A JP2011508615A JP2011508615A JP2011522796A JP 2011522796 A JP2011522796 A JP 2011522796A JP 2011508615 A JP2011508615 A JP 2011508615A JP 2011508615 A JP2011508615 A JP 2011508615A JP 2011522796 A JP2011522796 A JP 2011522796A
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acids
amino acid
nyad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522796A5 (OSRAM
Inventor
アシム クマール デブナス，
ホンタオ シャン，
フランセスカ カレリ，
Original Assignee
ニューヨーク ブラッド センター， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューヨーク ブラッド センター， インコーポレイテッド filed Critical ニューヨーク ブラッド センター， インコーポレイテッド
Publication of JP2011522796A publication Critical patent/JP2011522796A/ja
Publication of JP2011522796A5 publication Critical patent/JP2011522796A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011508615A 2008-05-06 2009-05-05 抗ウイルス細胞透過性ペプチド Pending JP2011522796A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5095508P 2008-05-06 2008-05-06
US61/050,955 2008-05-06
PCT/US2009/042913 WO2009137532A1 (en) 2008-05-06 2009-05-05 Antiviral cell penetrating peptides

Publications (2)

Publication Number Publication Date
JP2011522796A true JP2011522796A (ja) 2011-08-04
JP2011522796A5 JP2011522796A5 (OSRAM) 2012-02-02

Family

ID=40957984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508615A Pending JP2011522796A (ja) 2008-05-06 2009-05-05 抗ウイルス細胞透過性ペプチド

Country Status (6)

Country Link
US (2) US8324153B2 (OSRAM)
EP (1) EP2283033A1 (OSRAM)
JP (1) JP2011522796A (OSRAM)
AU (1) AU2009244400B2 (OSRAM)
CA (1) CA2725227A1 (OSRAM)
WO (1) WO2009137532A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535142A (ja) * 2019-06-07 2022-08-04 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ Ｈｉｖカプシドの阻害のためのペプチド阻害剤

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505831A (ja) * 2006-10-05 2010-02-25 ニューヨーク ブラッド センター， インコーポレイテッド 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
EP2283033A1 (en) * 2008-05-06 2011-02-16 New York Blood Center Antiviral cell penetrating peptides
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012137036A1 (en) * 2011-04-04 2012-10-11 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CA2834657A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN105622732B (zh) * 2014-10-30 2019-10-25 中国科学院武汉病毒研究所 猴病毒40衣壳蛋白vp1在作为细胞穿膜蛋白中的应用
LT3237436T (lt) 2014-12-24 2019-09-25 Aadigen, Llc Peptidai ir nanodalelės, skirti molekulių įvedimui į ląstelę
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
WO2019118893A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
CA3173973A1 (en) * 2020-03-04 2021-09-10 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
WO2001090197A1 (en) * 2000-05-26 2001-11-29 The Australian National University Synthetic peptides and uses therefore
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
ES2535961T3 (es) 1999-04-09 2015-05-19 Zoetis P&U Llc Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20020115606A1 (en) 2000-10-17 2002-08-22 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative diseases
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2008008998A2 (en) 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
US20100159477A1 (en) 2006-07-13 2010-06-24 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
CN101600447A (zh) 2006-09-11 2009-12-09 伊利诺斯大学理事会 铜氧还蛋白衍生肽类的修饰物及其使用方法
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5078401B2 (ja) * 2007-03-27 2012-11-21 株式会社Ａｄｅｋａ 防水シート
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
CA2713089C (en) 2008-01-23 2017-11-21 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
EP2283033A1 (en) * 2008-05-06 2011-02-16 New York Blood Center Antiviral cell penetrating peptides
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
WO2001090197A1 (en) * 2000-05-26 2001-11-29 The Australian National University Synthetic peptides and uses therefore
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535142A (ja) * 2019-06-07 2022-08-04 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ Ｈｉｖカプシドの阻害のためのペプチド阻害剤

Also Published As

Publication number Publication date
CA2725227A1 (en) 2009-11-12
US20130059776A1 (en) 2013-03-07
EP2283033A1 (en) 2011-02-16
AU2009244400A2 (en) 2010-11-11
AU2009244400A1 (en) 2009-11-12
US8933019B2 (en) 2015-01-13
AU2009244400B2 (en) 2012-12-20
US20090281041A1 (en) 2009-11-12
WO2009137532A1 (en) 2009-11-12
US8324153B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
AU2009244400B2 (en) Antiviral cell penetrating peptides
JP2011522796A5 (OSRAM)
ES2387827T3 (es) Péptidos antivirales helicoidales, de pequeño tamaño, terapéuticos estabilizados
JP2010209097A (ja) Ｈｉｖ感染のペプチド誘導体融合阻害剤
CN106749558B (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
CN111944025A (zh) 艾滋病病毒膜融合抑制剂脂肽及药物用途
AU2017410525B2 (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
US8937154B2 (en) Stabilized therapeutic small helical antiviral peptides
EP2291392B1 (en) Bifunctional molecules for inhibiting hiv entry
US20150111814A1 (en) Novel compositions for promoting hiv-1 virolysis and methods using same
WO2007068163A1 (en) Hiv fusion inhibitor peptides and use thereof
EP1594518A2 (en) Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41
WO2018141089A1 (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
Spensiero Design and synthesis of new integrase inhibitors
CA2766417A1 (en) Stabilized therapeutic small helical antiviral peptides
AU2012200580A1 (en) Stabilized therapeutic small helical antiviral peptides
Zhang Interaction-mediating sequences within class I viral fusion glycoproteins: their roles in viral infection and in applications
Simin Interaction-Mediating Sequences within Class I Viral Fusion Glycoproteins: Their Roles in Viral Infection and in Applications
WO2005068492A2 (en) Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection
Bailey The mechanism of HIV-1 virolytic inactivation by Env-targeting peptide triazole thiols
OA19487A (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof.
VOTTELER et al. Use of Synthetic Peptides for Structural and Functional Analyses of Viruses Like HIV
Poe Bimolecular fluorescence complementation reveals that HIV-1 Nef oligomerization is essential for CD4 downregulation and viral replication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131219